Dinutuximab - National Cancer Institute/United Therapeutics Corporation
At a glance
- Drug Originator National Cancer Institute (USA)
- Drug Licenced by Ohara Pharmaceutical; United Therapeutics Corporation
- Drug Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
- USA Patent Applicants UNITED THERAP
- USA Patents 28
- BLAs 1
- International Patents 93

Disclaimer